Objective: The International Mission on Prognosis and Analysis of Clinical Trials and Corticoid randomisation After significant Head injury prognostic models predict outcome after traumatic brain injury but have not been compared in large datasets. The objective of this is study is to validate externally and compare the International Mission on Prognosis and Analysis of Clinical Trials and Corticoid randomisation after significant Head injury prognostic models for prediction of outcome after moderate or severe traumatic brain injury.
T raumatic brain injury (TBI)
remains the main cause of death and disability in young adults worldwide (1, 2) . It is a heterogeneous disease with respect to cause, pathology, severity, and prognosis. This causes considerable uncertainty in the expected outcome of individual patients. Prognostic models can be used to combine different characteristics of an individual patient to predict outcome. Reliable outcome predictions can be used to provide realistic information to relatives, for more efficient design and analysis of clinical trials in TBI, and can provide a reference for assessing the quality of healthcare delivery (3) .
Many prognostic models for TBI have been developed in the past decades, with varying methodological quality (4, 5) . Only two sets of prognostic models were developed on large datasets and according to the latest methodological insights. These are the models developed on the International Mission on Prognosis and Analysis of Clinical trials in Traumatic brain injury database (IMPACT models) and the Corticosteroid Randomisation After Significant Head Injury trial data (CRASH models) (6, 7) .
Prognostic models are mathematical models developed from specific populations. External validation is necessary to determine the ability of a model to reliably predict outcome in populations, different from the development setting. Both the IMPACT models and the CRASH models have been externally validated previously, using each other's development datasets, indicating satisfactory generalizability. Nevertheless, a broader validation and comparison of these models has not yet been performed (8) .
In this study we aimed to validate externally the IMPACT and CRASH prognostic models in five relatively recent datasets and to compare these different models to predict mortality and unfavorable outcome.
MATERIALS AND METHODS

Models
Details of the development of the prognostic models were reported previously (6, 7) . In summary, the IMPACT models were developed on a dataset with 8,509 patients from 11 studies (i.e., three surveys and eight randomized controlled trials) on moderate and severe TBI (9) . Three different models were developed for the prediction of mortality and unfavorable outcome (Death, Vegetative State, Severe Disability), based on the dichotomized Glasgow Outcome Score (GOS) at 6 months after injury. These included the Core Model, the Extended Model, and the Lab Model (Table 1) . External validation was performed in patients with moderate to severe TBI enrolled in the CRASH trial dataset (n  6681).
The CRASH models were developed on the CRASH trial dataset (n  10,008) with patients who sustained mild, moderate, and severe TBI, mostly from low-and middle-income countries (n  7,526, 75%) (10, 11) . Two different models were developed for both the prediction of mortality at 2 wks after injury and unfavorable outcome at 6 months using the dichotomized GOS. The models included the Basic Model and the more extensive computed tomography (CT) Model ( Table 1 ). The IMPACT dataset (n  8509) was used for external validation.
Because the original CRASH models were developed for prediction of outcome in all TBI severity groups (including mild: Glasgow Coma Scale [GCS] scores [13] [14] [15] and not all variables of the CRASH models were available in the validation datasets (see below), we refitted an adapted version of the CRASH models in a selection of 6,681 patients with moderate to severe TBI (GCS 12), 14 yrs of age, and with available outcome data. In the refitted models, the total GCS score was replaced by the GCS motor score. Further, the Marshall CT classification and the presence of traumatic subarachnoid hemorrhage were included in the refitted CRASH CT model, instead of the original CT variables (Table 1) . New regression coefficients and intercepts were obtained for both the CRASH Basic and the CRASH CT models for prediction of mortality at 2 wks and unfavorable outcome at 6 months (Supplemental Digital Content 1, http://links.lww.com/CCM/ A400; and Supplemental Digital Content 2, http://links.lww.com/CCM/A401).
Datasets for External validation
National Acute Brain Injury Study: Hypothermia
The National Acute Brain Injury Study (NABIS) Hypothermia study (1994) (1995) (1996) (1997) (1998) ) was a multicenter randomized trial performed in the United States investigating the effect of hypothermia in severe TBI (12) . The primary outcome was the GOS at 6 months after injury. The trial was terminated after inclusion of 392 of the planned 500 patients because an interim analysis showed that the probability of detecting a treatment effect after expansion to 500 included patients was smaller than 1%. For the validation, we excluded patients younger than 14 yrs of age or with missing outcome (n  3), resulting in a dataset of 385 patients.
Cerestat
Cerestat is an unpublished, multicenter, randomized controlled trial in a combined group of North American and European centers investigating the effect of aptiganel HCl, a noncompetitive N-methyl-D-aspartate receptor antagonist, in severe TBI (GCS 8). In 1996 and 1997, 547 patients were enrolled in the trial. An interim analysis performed at the end of 1997 resulted in the decision that continuation of the trial was unjustified (13) . No benefit of the study drug was found in TBI patients. Since outcome was missing in 30 patients, a total of 517 were available for validation.
Apolipoprotein E
This single-center observational cohort study (1996) (1997) (1998) (1999) , Glasgow, Scotland) investigated the hypothesis that the possession of the apolipoprotein E (APOE) e4 allele is associated with a poor outcome after TBI (14). In total, 1,094 patients were enrolled, of whom 513 (54%) had a mild TBI (GCS 13-15). The outcome was the GOS at 6 months after injury. No overall association between the APOE genotype and outcome was found. To be consistent, we excluded patients with GCS >12 and age <14, resulting in a dataset with 404 patients.
Pharmos
The Pharmos dexanabinol study (2001) (2002) (2003) (2004) ) was a randomized, multicenter, placebocontrolled, phase III trial investigating the safety and efficacy of dexanabinol in patients with severe TBI carried out in Europe, Israel, Australia, and the United States (15) . The study enrolled 861 subjects. The study publication reported dexanabinol to be safe but not efficacious in the treatment of TBI. Because of missing 6-month outcome, five patients were excluded from our analyses, resulting in a dataset of 856 patients.
The Trauma Audit and Registry Network
Trauma Audit and Registry Network (TARN) is a hospital-based trauma registry in England and Wales including all patients with trauma resulting in immediate admission to hospital for 3 days or longer or death. The outcome measure is in-hospital mortality. For the validation, we selected patients 14 yrs of age enrolled between 2001 and 2009 with moderate or severe TBI (GCS 12), defined as having an Abbreviated Injury Scale Head score of 3 or higher, which was not resulting from scalp laceration, avulsion, or penetrating brain injury, with outcome data available, resulting in a dataset of 6,874 patients.
Data Analysis
The IMPACT and CRASH models (Table 1) were validated in these five validation datasets, all originated from high-income countries (Europe, North America, and Australia). Some models could not be applied to all datasets, because not all required predictor or outcome variables were available. Coding of the different predictors in the validation datasets was according to the IMPACT predictor coding as described previously (9) . Data on age, GCS motor score, pupillary reactivity, hypoxia, and hypotension were available for all validation datasets. However, in TARN, data on pupils were only collected in the latter years of inclusion, resulting in a large number of missing values with only 693 pupils available for 6,874 patients, 10%. Missing values occurred for several other predictors, mainly because some predictors were not collected in all studies. Table 2 includes information on the total number of patients included in the dataset and on the availability of the parameters of interest in these datasets. In TARN, some CT data were available (epidural hematoma and traumatic subarachnoid hemorrhage), but the Marshall CT Classification was not scored directly and therefore derived with an algorithm using the Abbreviated Injury Score as a basis (16) . Missing values were assumed to be missing at random and were statistically imputed. For the imputation procedure, the aregImpute function in R software was used (17) .
To quantify differences in the distribution of patient characteristics between the different studies, we calculated a summary measure of heterogeneity. This measure is defined as the sd of the linear predictor values of a logistic regression model, with mortality as the outcome variable, and age, GCS motor score, and pupillary reactivity as predictor variables. The linear predictor value is directly related to the predicted probability of mortality. In a relatively homogeneous population, the predicted probabilities -and thus linear predictor values -for all patients will be relatively close together, with a small sd. In a more heterogeneous population, the linear predictors will be more dispersed and the sd is larger.
Model Performance
We assessed the performance of the models in the new datasets in terms of discrimination and calibration. Discrimination describes how well a model distinguishes between patients with and without the outcome of interest. Calibration indicates how closely predicted outcomes match observed outcomes.
To assess discrimination, we calculated the area under the receiver operating characteristic curve (AUC). An AUC of 1 implies perfect discrimination, whereas an AUC of 0.5 implies that a model's discrimination is no better than chance. Discrimination in an external validation setting can be influenced in several ways. The predictor effects in the model can be different, resulting in an invalid model. But differences in the distribution of patient characteristics ("case mix") between the development and validation data may also influence discriminative power of the model. In a population with a prognostically homogeneous case mix, it will be more difficult to distinguish between patients with a good or poor outcome than in a heterogeneous population. For example, in an observational study with broad inclusion criteria, discrimination of a model will be better than in a strictly selected trial population.
To take these effects into account, we calculated two recently proposed benchmark values for the AUC: the case mix-corrected and the refitted AUC (18) . The case mix-corrected AUC indicates the discriminative power of a model, under the assumption that the predictor effects are fully correct for the validation population. It was calculated by simulating new outcome values for all patients in the validation dataset, based on the predicted risks for each patient calculated by the prognostic model. We performed 1000 repetitions to obtain stable estimates. The refitted AUC indicates the discriminative power that can be obtained by refitting the model in the validation dataset, resulting in new, optimal predictor effects. This resulted in an upper bound for the discriminative power, which would be found if the predictor effects in the validation dataset were exactly the same as in the development population.
To assess calibration, we plotted observed vs. predicted outcome. We assessed calibration-in-the-large by fitting a logistic regression model with the model predictions as an offset variable. The intercept indicates whether predictions are systematically too low or too high, and should ideally be zero. The calibration slope reflects the average effects of the predictors in the model and was estimated in a logistic regression model with the logit of the model predictions as the only predictor. For a perfect model, the slope is equal to 1.
The current study is part of the IMPACT project that was exempt from institutional review board approval. The analyses were performed using SPSS Statistics (Version 17.0.2, IBM Corporation, Somers, NY) and the R software environment (Version 2.7.1, The R Foundation for Statistical Computing, Vienna, Austria) with the Design and Hmisc packages.
RESULTS
Datasets
The observational series included a more heterogeneous case mix than the trial populations (Table 2 ). This was illustrated by the summary measure for heterogeneity: the strictly selected trial populations had a lower value (e.g., Pharmos: 0.58) than the observational series (e.g., TARN: 1.75).
The distributions of the GOS score for both the IMPACT and CRASH development datasets were U shaped (Fig. 1) . In NABIS, APOE, and Pharmos, the U-shaped outcome distribution had largely disappeared because a higher proportion of patients had severe disability: 26% in both NABIS and APOE and 29% in Pharmos, compared to 16% in IMPACT and 15% in CRASH. This resulted in a greater proportion of patients with unfavorable outcome. In IMPACT and CRASH, the proportions of unfavorable outcome were 48% and 47%, respectively, while in NABIS this was 56%, in APOE 53%, and in Pharmos 51%.
Model Performance Discrimination
Discrimination of the different models varied between the datasets (Table 3) . For prediction of mortality, AUCs varied between 0.65 and 0.83 for the IMPACT Core model and between 0.66 and 0.85 for the CRASH Basic model. For prediction of unfavorable outcome, AUCs between 0.66 and 0.76 were found for the IMPACT Core model and between 0.68 and 0.76 for the CRASH Basic model. Discrimination improved for both the IMPACT and CRASH models with increasing complexity of the models. Discrimination was better in the observational datasets (TARN and APOE) than in the trials, which was largely explained by a more heterogeneous case mix, compared to the development population (small difference between development for this dataset 14-day mortality was used instead of 6-month mortality as outcome for the model. AUC and case mix-corrected AUC, Table 3 ). When the model was refitted in the validation data, the performance was similar to the performance of the externally validated original model (small difference between external validation AUC and refitted AUC).
Calibration
The calibration slope and intercept values of the validation datasets and models are summarized in Table 3 .
In Pharmos, the calibration plots indicated some degree of miscalibration (Fig.2, A and B) . This was also expressed in the calibration slopes, indicating differences in predictor effects between the development and validation populations. For the IMPACT Core model the slopes were 0.733 for mortality and 0.634 for unfavorable outcome. The CRASH Basic model showed calibration slopes of 0.641 (mortality) and 0.645 (unfavorable outcome). In TARN (Fig. 3) , miscalibration was less apparent in the calibration plots. Calibration slopes were 1.318 (IMPACT Core model) and 1.375 (CRASH Basic model).
With regard to calibration-in-thelarge, in Pharmos, an intercept of 20.774 was found for mortality prediction with the IMPACT Core model, indicating that the model's predictions were moderately higher than the observed mortality. However, prediction of unfavorable outcome with the IMPACT Core model showed an intercept of 0.286, indicating mild underestimation of the outcome by the model. A similar pattern was observed for the CRASH Basic model. In TARN, the IMPACT Core model gave an intercept of 0.124 and the CRASH Basic model of 0.110 for prediction of mortality.
Sensitivity Analysis
Because of the high proportion of patients with missing data on pupillary reactivity in the TARN data, we also performed the validation in TARN patients with available data on pupillary reactivity (n  693). Compared to the validation with the imputed dataset, the results were very similar for both the IMPACT Models (Core: AUC  0.836, slope  
DISCUSSION
We confirmed the external validity of the IMPACT and CRASH prognostic models for prediction of outcome after moderate and severe TBI in five new datasets. Importantly, these datasets included both observational studies and clinical trials, thus permitting conclusions on generalizability. The predictive performance of the IMPACT and CRASH models was largely similar. Discrimination of the models varied between the different validation populations (clinical trials vs. observational studies). Overall, the more complex models performed better than the more simple models.
On average, performance measures did not substantially differ from those obtained in the development populations. Although developed on 6-month mortality or unfavorable outcome, the models also demonstrated good performance when predicting in-hospital mortality in the TARN registry.
These conclusions support the validity of these instruments to quantify prognostic risk in moderate and severe TBI.
Performance and Generalizability of Models
The CRASH and IMPACT prognostic models have been developed using stateof-the-art approaches on large datasets, and were externally validated reciprocally. They therefore meet methodological quality standards (17) . The IMPACT models have, however, been criticized for having, in part, been developed on older datasets, and the CRASH models for having been developed exclusively on data from a clinical trial -albeit one with broad enrollment criteria. Establishing their validity for current practice and their generalizability to other settings is therefore important. Panczykowski et al (19) reported good performance of the IMPACT models (AUC: 0.76-0.83) at validation on an unselected series of 587 patients with severe TBI admitted to a single level I trauma center. Honeybul et al (20) applied the CRASH model to a cohort of 147 TBI patients who underwent a decompressive craniectomy to predict outcome at 18 months after injury. The authors noted an overestimation of the predicted risk of unfavorable outcome, predominantly when the predicted risk was <80%. To our knowledge, no other validation studies on the IMPACT and CRASH models have been performed.
Assessing performance -and its interpretation -is a complex procedure, involving multiple levels. Many factors other than those directly related to the model itself may influence the performance of a model. These include changing epidemiology, trauma organization, different treatment policies, but also changes in approaches to outcome assessment. Such external factors could influence the validity of the predictor effects (regression coefficients) and the distribution of the predictor values in the new population (case mix).
We observed clear effects of the case mix on discrimination: higher AUCs were found in the observational series (TARN and APOE) compared to the randomized controlled trials. These higher AUCs reflect the less restrictive enrollment criteria: the greater the heterogeneity, the better the models can distinguish patients with very low or very high predictions. We therefore strongly discourage the indiscriminate comparisons of reported AUCs between different studies without taking the case mix of the development and validation population into consideration. Use of the case mix-corrected AUC as proposed by Vergouwe et al (18) would appear more appropriate, as illustrated by the decrease in AUC observed in the observational series vs. the increase observed in the randomized controlled trials when calculating the case mix-corrected AUC (Table 3) .
With regard to calibration, we did observe some indication for differences in predictor effects between the development and validation datasets. Particularly noteworthy is the discrepancy in the calibration slopes for the Pharmos and NABIS trials: the observed mortality is lower than predicted, while the number of patients with an unfavorable outcome is substantially higher than predicted. This discrepancy could be explained by a greater number of patients with severe disability than expected. Although some difference in predictor effects may be present, we consider the different outcome distribution (Fig. 1 ) a more likely explanation. The main question then becomes what may have caused this change. It may be that approaches to outcome assessment, and in particular to the assignment of outcome categories, have changed. Pharmos and NABIS used the structured interview as a means to better standardize outcome assignment, and in the Pharmos trial, a central review of outcome assignments was performed (21). Wilson et al (22) reported that central assignments were generally worse, causing a shift toward more severe disability. Our findings indicate that changes in the approach to assessment of the GOS may influence both outcome distribution and predictor effects. Clarification of this issue is considered essential and requires a dedicated prospective study. The need for such a study is becoming more pertinent following the recent proposals by Lu et al (23) for yet another new approach to assessing the extended GOS.
IMPACT or CRASH Models?
We have often been asked the question of which model should be preferred: CRASH or IMPACT?
The current validation studies do not indicate any clear preference. Both models demonstrated comparable performance on external validation. A difference between the IMPACT and CRASH models is the inclusion of major extracranial injury as a predictor in the CRASH models. We, however, found that the added prognostic effect of major extracranial injury in our validation series was negligible (results not shown), which may have resulted from the case mix of the validation datasets. In a recent meta-analysis of IMPACT, CRASH, and TARN data, we found an interaction between major extracranial injury and the clinical severity: only small effects of major extracranial injury were noted in patients with severe TBI, while in mild TBI, the presence of extracranial injury had a strong prognostic effect (24) .
Perhaps the most appropriate answer to the question of which model should be preferred is to consider the setting and case mix of the population under study. The IMPACT models were developed on patients with moderate and severe TBI, mostly from high-income countries. The development population for the CRASH models also included patients with mild TBI and a substantial number of patients from low-and middle-income countries. Consequently, a preference may be expressed for the CRASH models when the population under study includes patients with mild TBI or patients from low-and middle-income countries.
Limitations
Our study has some limitations. First, due to differences in recorded predictor and outcome variables, it was not possible to validate the original CRASH models. As described above, we refitted the CRASH models in a selection of the CRASH trial data (GCS 12) with a different definition of the CT variables and the GCS motor score instead of the full GCS score. This resulted in an adapted version of the CRASH models, making them more similar to the IMPACT models. Nevertheless, some aspects of the adapted CRASH models were still substantially different from the IMPACT models. These differences included the inclusion of the presence of major extracranial injury as a predictor in the CRASH models and the inclusion of second insults (hypoxia and hypotension) as predictors to the IMPACT Extended and Lab models. Further, the adapted CRASH models were developed to predict early (14-day) mortality and the IMPACT models late (6-month) mortality.
It was not possible to validate all models to all new datasets, since not all required predictor and outcome variables were recorded for each dataset. In TARN, the 6-month GOS was not recorded as an outcome measure, and only the models predicting mortality were validated on these data. Although the outcome measure was in-hospital mortality, instead of 14-day or 6-month mortality, both IMPACT and CRASH models performed well.
In TARN, actual CT data were not available, but derived from extensive coding of the Abbreviated Injury Score according to an algorithm proposed by Lesko et al (16) . The Abbreviated Injury Score codes were, however, not only based on data of imaging studies at admission, but also upon information of later imaging studies (CT and magnetic resonance imaging), as well as findings during surgery. Servadei et al (25) have previously demonstrated that the "worst" CT may demonstrate more abnormalities than the admission CT.
A further limitation was the high proportion of missing values on pupillary reactivity in the TARN dataset (90%). Since it would be a waste of information to exclude all patients with missing pupils (6,181 patients with a total of 49,496 data points), we decided to include these patients for the validation and to statistically impute the missing values with an imputation model. Both theoretical and empirical support is growing for the use of such imputation methods instead of traditional complete case analyses (17) . As a sensitivity analysis, we also performed the validation in a complete case dataset of TARN, which showed very similar results, supporting the validity of the approaches taken. The lack of availability of some important predictors in some datasets and missing data in others illustrates the paramount importance of standardization of data collection and coding of variables, as proposed in the common data elements initiative (26) .
CONCLUSIONS
This external validation study confirms the validity of both the IMPACT and CRASH models in more recent datasets, with best performance in more heterogeneous observational series. Model performance improved slightly with increasing complexity of the models, but most information is captured in three key predictors: age, GCS motor score, and pupillary reactivity. No relevant difference in performance was found between the IMPACT and the CRASH models. These findings confirm generalizability of the models in new data and support the use of the models for a wide range of applications. These include the classification of future TBI patient populations (especially exploiting the discriminative ability of the models) and calculation of the baseline prognostic risk of individual patients (requiring good calibration of the models).
It may be expected that the effects of treatment and healthcare organization on outcome of individual patients change over time. This underlines the necessity of revalidation of these prognostic models in the future to reconfirm generalizability or to update the models on more recent patient populations. This should become a continuing process, and highlights the need for a prospective high quality observational study.
